ArticleJournal of virology2025
Tetraspanin CD81 serves as a functional entry factor for porcine circovirus type 2 infection.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tetraspanin SfCD9 as a Key Membrane Binding Factor of SRBSDV P10 Facilitates Viral Entry Into Sogatella furcifera Midgut Epithelial Cells via Clathrin-Mediated Endocytosis.Molecular plant pathology · 2025Article
- Importinα3 Mediates BmNPV Nucleocapsid Nuclear Entry via a Ran-Independent Pathway.Current microbiology · 2025Article
- Circovirus Rep evades immune restriction by disrupting cGAS oligomerization and phase separation.PLoS pathogens · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine circovirus type 2 (PCV2) is the primary causative agent of porcine circovirus-associated disease, clinically resulting in immunosuppression and co-infections with other pathogens in infected pigs. The mechanism of PCV2 infection remains unclear. In this study, we firstly found that the tetraspanin CD81 in PK-15 cells interacts with PCV2 Cap protein by using virus overlay protein-binding assay combined with mass spectrometry. Knockdown of the CD81 significantly reduces the levels of the viral Cap mRNA and protein, and viral internalization in PK-15 cells. The critical interaction regions locate in the large extracellular loop (LEL) domain of CD81 and the CD loop region (82-91aa) of the Cap protein, and a polyclonal antibody against the CD81 LEL domain significantly inhibits PCV2 infection. The transmembrane proteoglycan Syndecan-1 interacts with both CD81 and PCV2 Cap, and co-operates with CD81 to promote PCV2 infection in PK-15 cells. Furthermore, CD81 facilitates RhoA activation and enhances the viral internalization and replication in PK-15 cells. It was concluded that the tetraspanin CD81 is a key host factor for PCV2 invasion into PK-15 cells, thus providing new insights into PCV2 life cycle and identifying a potential target for antiviral drug development.IMPORTANCEPorcine circovirus type 2 (PCV2), a significant economic pathogen in the swine industry, presents persistent challenges in its prevention and treatment. Despite extensive research, the mechanism of PCV2 invading host cells remains unclear. In this study, we found and identified a novel interaction between the tetraspanin CD81 and the viral Cap protein during the PCV2 invading PK-15 cells. The transmembrane proteoglycan Syndecan-1 and RhoA are involved in the infection process through the CD81. Moreover, this is the first time that the role of Syndecan-1 in the PCV2 infection process has been demonstrated. Also, a polyclonal antibody against the CD81 extracellular domain significantly inhibits PCV2 infection in PK-15 cells. It not only enriches our understanding of PCV2 life cycle but also offers new perspectives for the development of antiviral therapeutics against circovirus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.